Navigation Links
Tigris Pharmaceuticals Files IND Application for GGTI-2418
Date:2/6/2009

BONITA SPRINGS, Fla., Feb. 6 /PRNewswire/ -- Tigris Pharmaceuticals, Inc., a privately held drug development company, announced today that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for GGTI-2418, a novel anticancer compound. GGTI-2418 is a synthetic peptidomimetic inhibitor of geranylgeranyltransferase I (GGTase I) that appears to induce apoptosis by downregulating several pivotal oncogenic and tumor survival pathways.

"The filing of this IND ahead of the scheduled date represents a major corporate achievement for the entire Tigris team," said Edmundo Muniz, M.D., Ph.D., President and Chief Executive Officer of Tigris. "Pending acceptance by the FDA, we plan to initiate a Phase 1 study of GGTI-2418 in two top Phase I cancer research centers in the first half of 2009. This will be the first geranylgeranyltransferase inhibitor in human clinical trials in this well-validated pathway and represents an important advancement in identifying novel approaches to treat cancer."

"The submission of this IND marks an extremely important and exciting time in the field of geranylgeranylation inhibitors. I look forward to the fruitful translation of our preclinical work to target patients whose tumors harbor aberrant signal transduction pathways most likely to respond to GGTI-2418," stated Said M. Sebti, Ph.D., Director of the Drug Discovery Program at the Moffitt Cancer Center and co-inventor of GGTI-2418. "This is a most important and gratifying step in the development of GGTI-2418 as a novel treatment for the devastating effects of cancer," noted Andrew Hamilton, Ph.D., Professor of Chemistry at Yale University and co-inventor of GGTI-2418.

Tigris in-licensed the exclusive worldwide rights to GGTI-2418 from Yale University and the University of South Florida.

About GGTI-2418

GGTI-2418 is
'/>"/>

SOURCE Tigris Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Corrected: XTL Biopharmaceuticals to Convene Extraordinary Shareholders Meetings after Receipt of Shareholder Letter
2. XTL Biopharmaceuticals to Convene Extraordinary Shareholders Meetings after Receipt of Shareholder Letter
3. Transcept Pharmaceuticals to Present at 11th Annual BIO CEO & Investor Conference
4. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
5. Poniard Pharmaceuticals to Present at the BIO CEO & Investor Conference
6. Amylin Pharmaceuticals Confirms Receipt of Director Nomination Notices
7. Endo Pharmaceuticals to Announce Fourth Quarter and 2008 Full-Year Financial Results on February 27, 2009
8. XTL Biopharmaceuticals Announces Receipt of NASDAQ Notice of Delisting
9. XTL Biopharmaceuticals Provides Update on Potential Strategic Alternatives
10. Indevus Pharmaceuticals Announces Release of 2008 Annual Report
11. Amylin Pharmaceuticals Appoints Vincent Mihalik Senior Vice President, Sales and Marketing and Chief Commercial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... DUBLIN , Sep. 02, 2015 ... ) has announced the addition of Jain PharmaBiotech,s ... Markets and Companies" to their offering. ... markets based on technologies and applications. The report ... basis for estimation of markets. Technologies include array ...
(Date:9/2/2015)... 02, 2015 ... announced the addition of Jain PharmaBiotech,s new ... Companies" to their offering. ... besides fluorescence in situ hybridization (FISH), comparative ... cytogenetics includes application of nanobiotechnology, microarrays, real-time ...
(Date:9/2/2015)... , Sept. 2, 2015 Australian prostate ... a prestigious Australian science prize recognising ,outstanding, science that ... track to globally launch a novel prostate cancer diagnostic ... a high level consortium taking out the peer-reviewed Australian ... Scientific Research. This prize is awarded ...
(Date:9/2/2015)... ZIONA, Israel , September 2, ... TASE: BVXV) today announced the intent of the National Institute ... National Institutes of Health (NIH) within the Department of Health ... trial to be held in the United States ... the use of BiondVax,s universal flu vaccine candidate, Multimeric-001 (M-001), ...
Breaking Biology Technology:Global Biochips and Microarrays Technologies, Markets and Companies Report 2015 with Market Size in 2014 and Projected Value for the Years 2019 and 2024 2Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 2Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 3Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 2Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 3BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3
... Oct. 29 MannKind,Corporation (Nasdaq: MNKD ) will ... 5, 2008 at 8:00 a.m. EST., Management of ... the,third quarter financial results, clinical progress and other Company,developments ... from the,Company will be its Chairman and Chief Executive ...
... (Nasdaq: SGMO ) today reported third quarter 2008,financial ... September 30, 2008, Sangamo reported a,consolidated net loss of ... loss of $4.3 million, or $0.11 per share, for ... the company had cash, cash equivalents and,investments of $59.5 ...
... Pharmaceuticals Inc.,(Nasdaq: TRBN ) today announced that executives ... at two upcoming industry and/or investor,conferences:, -- Nov. ... the,New York Palace Hotel, 455 Madison Ave. in New ... president, is scheduled to present,at 9:55 a.m. EST., ...
Cached Biology Technology:MannKind Corporation to Hold Third Quarter Financial Results Conference Call on November 5, 2008 2Sangamo BioSciences Reports Third Quarter 2008 Financial Results 2Sangamo BioSciences Reports Third Quarter 2008 Financial Results 3Sangamo BioSciences Reports Third Quarter 2008 Financial Results 4Sangamo BioSciences Reports Third Quarter 2008 Financial Results 5Sangamo BioSciences Reports Third Quarter 2008 Financial Results 6Sangamo BioSciences Reports Third Quarter 2008 Financial Results 7Trubion Announces Presentations at Upcoming Investor Conferences 2
(Date:8/6/2015)... 2015  Today, U.S. Congressman Mike Honda ... to learn firsthand how Silicon Valley technologies can ... a world leader in multi-factor identity management and ... federal agencies and commercial organizations achieve new levels ... "The vast majority of network breaches can be ...
(Date:8/5/2015)... August 5, 2015 According to ... Management Market by Software, Services, Vertical (BFSI, Airport, IT & ... - Global Forecast to 2020", published by MarketsandMarkets, defines ... globally into various segments. The global PIAM Market is ... $546.2 Million by 2019, at a CAGR of 14.9 ...
(Date:8/4/2015)... 2015 Research ... the addition of the "Digital Forensics ... Sub-Segment (Computer Forensics, Network Forensics, Mobile Device ... Vertical and Region - Global Forecast to ... By Component (Hardware, Software, and Service), ...
Breaking Biology News(10 mins):Rep. Honda to Visit Crossmatch in Redwood City 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2
... gene they suspect plays an important role in triggering ... century-and-a-half ago. , And the pathogen that contains this ... the modern world?on the order of billions of dollars ... Avr3a, in a study that appears online in the ...
... Created as an alternate route of drug administration to ... skin patches are rapidly becoming an important healthcare product ... of chronic conditions such as angina, hypertension and HRT, ... transdermal patches for a host of new conditions wind ...
... Microarray technology can be used to identify each stage ... newly published report. , Melanomas grow in two phases: ... metastasize (spread cancer to other parts of the body) ... a large primary melanoma into radial and vertical portions, ...
Cached Biology News:Researchers find gene that may be at root of potato blight 2Researchers find gene that may be at root of potato blight 3
... ISO 9001:2000 Certified USDA Research Registered OLAW ... Training AALAS Certified Technicians ... GLP Documentation Upon Request Focus ... for all your custom immunology service needs. ...
biotin-4-fluorescein...
Human IL-17D Affinity Purified Polyclonal Ab...
Agar, 5 lb. Bacteriological.Moisture: < 10%, ash: < 6.5%. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Biology Products: